

Resource Summary Report

Generated by ASWG on Aug 29, 2026

Recombinant Anti-TNF alpha antibody [RM1005]

RRID:AB_2941996

Type: Antibody

Proper Citation

Abcam Cat# ab307164, RRID:AB_2941996

Antibody Information

URL: http://antibodyregistry.org/AB_2941996

Proper Citation: Abcam Cat# ab307164, RRID:AB_2941996

Target Antigen: TNF alpha

Host Organism: rabbit

Clonality: recombinant polyclonal

Comments: Applications: WB, IHC-P, ICC/IF, Flow Cyt

Antibody Name: Recombinant Anti-TNF alpha antibody [RM1005]

Description: This recombinant polyclonal targets TNF alpha

Target Organism: rat, mouse, human

Clone ID: RM1005

Antibody ID: AB_2941996

Vendor: Abcam

Catalog Number: ab307164

Record Creation Time: 20250820T052300+0000

Record Last Update: 20250820T212712+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-TNF alpha antibody [RM1005].

No alerts have been found for Recombinant Anti-TNF alpha antibody [RM1005].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Seo J, et al. (2026) KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer. *Frontiers in oncology*, 16, 1765625.

Ilhan I, et al. (2026) The role of fluvoxamine in the treatment of endotoxin-induced acute heart injury. *British journal of pharmacology*, 183(13), 3815.

Chen W, et al. (2025) Static magnetic fields alleviate diabetic nephropathy by reducing renal cell inflammation and promoting M2 macrophage polarization. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(5), e70424.

Imani-Almas E, et al. (2025) 4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia. *Metabolic brain disease*, 40(7), 264.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8), 112944.